Rion Co., Ltd. (TYO:6823)
Japan · Delayed Price · Currency is JPY 2,654.00
-46.00 (-1.70%)
Aug 14, 2025, 3:30 PM JST
ASLAN Pharmaceuticals Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Revenue | 28,151 | 27,877 | 25,726 | 23,868 | 22,635 | 20,466 | Upgrade |
Revenue Growth (YoY) | 7.99% | 8.36% | 7.78% | 5.45% | 10.60% | -4.65% | Upgrade |
Cost of Revenue | 14,118 | 13,815 | 12,681 | 12,165 | 11,257 | 10,238 | Upgrade |
Gross Profit | 14,033 | 14,062 | 13,045 | 11,703 | 11,378 | 10,228 | Upgrade |
Selling, General & Admin | 9,013 | 9,180 | 8,618 | 7,945 | 7,359 | 7,241 | Upgrade |
Research & Development | 782 | 782 | 889 | 887 | 926 | 764 | Upgrade |
Operating Expenses | 9,861 | 10,028 | 9,571 | 8,858 | 8,273 | 8,007 | Upgrade |
Operating Income | 4,172 | 4,034 | 3,474 | 2,845 | 3,105 | 2,221 | Upgrade |
Interest Expense | -2.2 | -2 | -1 | -2 | -1 | -1 | Upgrade |
Interest & Investment Income | 51.92 | 44 | 45 | 28 | 22 | 31 | Upgrade |
Currency Exchange Gain (Loss) | -3.56 | 2 | 9 | 87 | 53 | - | Upgrade |
Other Non Operating Income (Expenses) | 128.21 | 26 | 35 | 49 | 32 | 45 | Upgrade |
EBT Excluding Unusual Items | 4,347 | 4,104 | 3,562 | 3,007 | 3,211 | 2,296 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 50 | 55 | - | -9 | Upgrade |
Gain (Loss) on Sale of Assets | 0.72 | - | - | - | - | 1 | Upgrade |
Asset Writedown | -41 | -41 | -18 | -379 | -40 | -55 | Upgrade |
Other Unusual Items | -164 | -164 | -77 | -299 | - | 190 | Upgrade |
Pretax Income | 4,143 | 3,899 | 3,517 | 2,384 | 3,171 | 2,423 | Upgrade |
Income Tax Expense | 1,089 | 1,040 | 865 | 585 | 942 | 787 | Upgrade |
Net Income | 3,053 | 2,859 | 2,652 | 1,799 | 2,229 | 1,636 | Upgrade |
Net Income to Common | 3,053 | 2,859 | 2,652 | 1,799 | 2,229 | 1,636 | Upgrade |
Net Income Growth | 28.88% | 7.80% | 47.41% | -19.29% | 36.25% | -8.04% | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 12 | 12 | Upgrade |
Shares Change (YoY) | 0.08% | 0.07% | 0.07% | 0.07% | 0.05% | 0.05% | Upgrade |
EPS (Basic) | 247.87 | 232.14 | 215.49 | 146.28 | 181.38 | 133.19 | Upgrade |
EPS (Diluted) | 247.87 | 232.14 | 215.49 | 146.28 | 181.38 | 133.19 | Upgrade |
EPS Growth | 28.79% | 7.73% | 47.31% | -19.35% | 36.18% | -8.08% | Upgrade |
Free Cash Flow | - | 2,138 | 725 | 473 | 2,310 | 1,241 | Upgrade |
Free Cash Flow Per Share | - | 173.59 | 58.91 | 38.46 | 187.97 | 101.03 | Upgrade |
Dividend Per Share | 65.000 | 65.000 | 50.000 | 45.000 | 45.000 | 43.000 | Upgrade |
Dividend Growth | 30.00% | 30.00% | 11.11% | - | 4.65% | - | Upgrade |
Gross Margin | - | 50.44% | 50.71% | 49.03% | 50.27% | 49.98% | Upgrade |
Operating Margin | 14.82% | 14.47% | 13.50% | 11.92% | 13.72% | 10.85% | Upgrade |
Profit Margin | 10.85% | 10.26% | 10.31% | 7.54% | 9.85% | 7.99% | Upgrade |
Free Cash Flow Margin | - | 7.67% | 2.82% | 1.98% | 10.21% | 6.06% | Upgrade |
EBITDA | 5,498 | 5,275 | 4,375 | 3,588 | 3,809 | 2,955 | Upgrade |
EBITDA Margin | - | 18.92% | 17.01% | 15.03% | 16.83% | 14.44% | Upgrade |
D&A For EBITDA | 1,326 | 1,241 | 901 | 743 | 704 | 734 | Upgrade |
EBIT | 4,172 | 4,034 | 3,474 | 2,845 | 3,105 | 2,221 | Upgrade |
EBIT Margin | - | 14.47% | 13.50% | 11.92% | 13.72% | 10.85% | Upgrade |
Effective Tax Rate | - | 26.67% | 24.59% | 24.54% | 29.71% | 32.48% | Upgrade |
Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.